Literature DB >> 32083493

Targeting anti-apoptotic BCL-2 family proteins for cancer treatment.

Xuan Zhang1, Xingui Liu2, Daohong Zhou2, Guangrong Zheng1.   

Abstract

Entities:  

Keywords:  BCL-2; BCL-XL; MCL-1; apoptosis; cancer treatment

Mesh：

Substances：

Year:  2020        PMID： 32083493     DOI： 10.4155/fmc-2020-0004

Source DB:  PubMed          Journal:  Future Med Chem        ISSN： 1756-8919            Impact factor:   3.808


× No keyword cloud information.
  10 in total

1.  Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines.

Authors:  Xuan Zhang; Yonghan He; Peiyi Zhang; Vivekananda Budamagunta; Dongwen Lv; Dinesh Thummuri; Yang Yang; Jing Pei; Yaxia Yuan; Daohong Zhou; Guangrong Zheng
Journal:  Eur J Med Chem       Date:  2020-05-04       Impact factor: 6.514

2.  Anti-Tumorigenic Effect of a Novel Derivative of 2-Hydroxyoleic Acid and the Endocannabinoid Anandamide on Neuroblastoma Cells.

Authors:  Hana Golan; Raphael Mechoulam; Reem Smoum; Efrat Cohen-Zada; Sara Pri-Chen; Sapir Wiener; Igor Grinberg; Dekel D Bar-Lev; Christeeneh G Haj; Tamar Fisher; Amos Toren
Journal:  Biomedicines       Date:  2022-06-29

3.  Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer.

Authors:  Ming Zhao; Stephen Scott; Kurt W Evans; Erkan Yuca; Turcin Saridogan; Xiaofeng Zheng; Heping Wang; Anil Korkut; Christian X Cruz Pico; Mehmet Demirhan; Bryce Kirby; Scott Kopetz; Irmina Diala; Alshad S Lalani; Sarina Piha-Paul; Funda Meric-Bernstam
Journal:  Clin Cancer Res       Date:  2021-01-07       Impact factor: 13.801

4.  Retrospective Analysis of Clinicopathological Characteristics of Lacrimal Gland Pleomorphic Adenoma and Mechanism of Tumorigenesis by the Imbalance Between Apoptosis and Proliferation.

Authors:  Meng Lv; Zhi-Jun Dong; Yue-Xin Tong; Tian Li; Yan Hei; Xin-Ji Yang; Wei-Li Dong
Journal:  Med Sci Monit       Date:  2021-03-19

5.  Luteolin enhances erlotinib's cell proliferation inhibitory and apoptotic effects in glioblastoma cell lines.

Authors:  Erika Powe; Daniel Parschauer; Jessica Istifan; Stacy Lin; Huanyun Duan; Rebecca Gryka; Denise Jean-Louis; Amit K Tiwari; Samson Amos
Journal:  Front Pharmacol       Date:  2022-09-19       Impact factor: 5.988

Review 6.  Programmed cell death, redox imbalance, and cancer therapeutics.

Authors:  Xiaofeng Dai; Danjun Wang; Jianying Zhang
Journal:  Apoptosis       Date:  2021-07-08       Impact factor: 4.677

7.  PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors.

Authors:  Peiyi Zhang; Xuan Zhang; Xingui Liu; Sajid Khan; Daohong Zhou; Guangrong Zheng
Journal:  Explor Target Antitumor Ther       Date:  2020-08-31

8.  Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance.

Authors:  Wei Wu; Jessica L Klockow; Michael Zhang; Famyrah Lafortune; Edwin Chang; Linchun Jin; Yang Wu; Heike E Daldrup-Link
Journal:  Pharmacol Res       Date:  2021-07-21       Impact factor: 10.334

Review 9.  Killing by Degradation: Regulation of Apoptosis by the Ubiquitin-Proteasome-System.

Authors:  Ruqaia Abbas; Sarit Larisch
Journal:  Cells       Date:  2021-12-08       Impact factor: 6.600

10.  Targeting cancer with antibody-drug conjugates: Promises and challenges.

Authors:  Alexis Q Dean; Shen Luo; Julianne D Twomey; Baolin Zhang
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.